Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Hallie Wimberly"'
Autor:
Vasiliki Pelekanou, Daniel E. Carvajal-Hausdorf, Mehmet Altan, Brad Wasserman, Cristobal Carvajal-Hausdorf, Hallie Wimberly, Jason Brown, Donald Lannin, Lajos Pusztai, David L. Rimm
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-11 (2017)
Abstract Background The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) protein expression
Externí odkaz:
https://doaj.org/article/c250518058be4c34b284ca5bdaf2582c
Publikováno v:
BioTechniques, Vol 52, Iss 4, Pp 235-245 (2012)
MicroRNAs (miRNAs) have emerged as key regulators in the pathogenesis of cancers where they can act as either oncogenes or tumor suppressors. Most miRNA measurement methods require total RNA extracts which lack critical spatial information and presen
Externí odkaz:
https://doaj.org/article/a0ddfa3d17634a20a8de65aa56e2c859
Autor:
Vasiliki Pelekanou, Daniel E. Carvajal-Hausdorf, Mehmet Altan, Brad Wasserman, Cristobal Carvajal-Hausdorf, Hallie Wimberly, Jason Brown, Donald Lannin, Lajos Pusztai, David L. Rimm
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-1 (2017)
Externí odkaz:
https://doaj.org/article/e68dfb67828a4b178ae05ffbd202483e
Autor:
David L. Rimm, Donald R. Lannin, Lajos Pusztai, Veerle Bossuyt, Christian Nixon, Matthew R. Silver, Herbert Haack, Kurt Schalper, Jason R. Brown, Hallie Wimberly
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dab2fc0c1cd1a821ea93a9566419265
https://doi.org/10.1158/2326-6066.22537544.v1
https://doi.org/10.1158/2326-6066.22537544.v1
Autor:
David L. Rimm, Donald R. Lannin, Lajos Pusztai, Veerle Bossuyt, Christian Nixon, Matthew R. Silver, Herbert Haack, Kurt Schalper, Jason R. Brown, Hallie Wimberly
Supplemental Fig 1. Epithelial and stromal PD-L1 expression. Supplemental Fig 2. Validation of specificity of PD-L1 antibody used in this study. Supplemental Fig 3. Correlation with PD-L1 expression and pCR in patient subsets. Supplemental Fig 4. Joi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfefcbd0a1d2aac989a88cb69ddef589
https://doi.org/10.1158/2326-6066.22537541.v1
https://doi.org/10.1158/2326-6066.22537541.v1
Autor:
David L. Rimm, Donald R. Lannin, Lajos Pusztai, Veerle Bossuyt, Christian Nixon, Matthew R. Silver, Herbert Haack, Kurt Schalper, Jason R. Brown, Hallie Wimberly
Supplemental Table 1. Exclusion of Ki67 from Table 4 shows that both stromal and epithelial PD-L1 expressions are highly significant in multivariate analysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8291c5cc1eafd529dfff408261c5d85e
https://doi.org/10.1158/2326-6066.22537547.v1
https://doi.org/10.1158/2326-6066.22537547.v1
Autor:
David L. Rimm, Donald R. Lannin, Lajos Pusztai, Veerle Bossuyt, Christian Nixon, Matthew R. Silver, Herbert Haack, Kurt Schalper, Jason R. Brown, Hallie Wimberly
Programmed death 1 ligand 1 (PD-L1) is an immune regulatory molecule that limits antitumor immune activity. Targeting of PD-L1 and other immune checkpoint proteins has shown therapeutic activity in various tumor types. The expression of PD-L1 and its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81de45052a546b7554ad2f94025cebc5
https://doi.org/10.1158/2326-6066.c.6548471.v1
https://doi.org/10.1158/2326-6066.c.6548471.v1
Autor:
David L. Rimm, Lajos Pusztai, Jason Brown, Hallie Wimberly, Daniel Carvajal, Vamsidhar Velcheti, Kurt A. Schalper
PDF file - 73K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a5f1e0418efd574b723a6f7845cd3e1
https://doi.org/10.1158/1078-0432.22448318.v1
https://doi.org/10.1158/1078-0432.22448318.v1
Autor:
David L. Rimm, Lajos Pusztai, Jason Brown, Hallie Wimberly, Daniel Carvajal, Vamsidhar Velcheti, Kurt A. Schalper
Purpose: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1 protein expression may predict response to drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fde5bd044b95ccb346616f2bc4254ce
https://doi.org/10.1158/1078-0432.c.6521369
https://doi.org/10.1158/1078-0432.c.6521369
Autor:
Veerle Bossuyt, David L. Rimm, Christian Nixon, Donald R. Lannin, Hallie Wimberly, Jason R. Brown
Purpose: Although tumor-infiltrating lymphocytes (TIL) have been associated with response to neoadjuvant therapy, measurement typically is subjective, semiquantitative, and unable to differentiate among subpopulations. Here, we describe a quantitativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aaab08b7c17dbe597c8999bcca31d37
https://doi.org/10.1158/1078-0432.c.6522942
https://doi.org/10.1158/1078-0432.c.6522942